Consequently, the administration of a selective COX-2 inhibiting agent and a DNA topoisomerase I inhibitor, in combination with an agent, or agents, that inhibits or suppresses oncogenes is contemplated to prevent or treat cancers in which oncogenes are overexpressed. [0359] Accordingly, there is a need for a method of treating or preventing a cancer in a patient that overexpresses COX-2 and/or an